Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia

被引：29
|
作者：
Rabello, Doralina do Amaral [1 ]
Lucena-Araujo, Antonio Roberto [2 ]
Rocha Alves-Silva, Juliana Carvalho [1 ]
Aboud Souza da Eira, Vinicius Burnett [1 ]
Cals de Vasconcellos, Maria Catarina [3 ]
de Oliveira, Fabio Morato [2 ]
Rego, Eduardo Magalhaes [2 ]
Saldanha-Araujo, Felipe [1 ]
Silva, Fabio Pittella [1 ]
机构：
[1] Univ Brasilia, Lab Mol Pathol Canc, BR-70910900 Brasilia, DF, Brazil
[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Internal Med, BR-14048900 Ribeirao Preto, SP, Brazil
[3] Hosp Base Dist Fed, Setor Hosp Sul, Area Especial, BR-70330150 Brasilia, DF, Brazil
来源：
BLOOD CELLS MOLECULES AND DISEASES | 2015年 / 54卷 / 01期
关键词：
Chronic lymphocytic leukemia; EZH2; Histone methyltransferase; Gene expression; Cytogenetic; ZAP-70; EXPRESSION; POLYCOMB; MECHANISMS; DIAGNOSIS; CELLS;
D O I：
10.1016/j.bcmd.2014.07.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码：97 / 102
页数：6
相关论文
共 50 条
  • [1] EZH2 overexpression is associated with poor prognosis in patients with glioma
    Zhang, Yanyang
    Yu, Xinguang
    Chen, Ling
    Zhang, Zhibin
    Feng, Shiyu
    ONCOTARGET, 2017, 8 (01) : 565 - 573
  • [2] EZH2 overexpression as a biomarker of poor prognosis in prostate cancer
    Gu, Xiaobin
    Gao, Xian-Shu
    Bai, Yun
    Cui, Ming
    Xiong, Wei
    Han, Linjun
    Guo, Wei
    Xie, Mu
    Peng, Chuan
    Su, Mengmeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 21829 - 21835
  • [3] Overexpression of the Histone Methyltransferase EZH2 in Chronic Lymphocytic Leukemia Confers Protection from Apoptosis and Is Linked to Clinical Aggressiveness
    Papakonstantinou, Nikos
    Ntoufa, Stavroula
    Chartomatsidou, Elisavet
    Agathangelidis, Andreas
    Karamanli, Tzeni
    Anagnostopoulos, Achilles
    Ghia, Paolo
    Rosenquist, Richard
    Belessi, Chrysoula
    Stamatopoulos, Kostas
    BLOOD, 2014, 124 (21)
  • [4] Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
    Sun, Ranran
    Shen, Jacson
    Gao, Yan
    Zhou, Yubing
    Yu, Zujiang
    Hornicek, Francis
    Kan, Quancheng
    Duan, Zhenfeng
    ONCOTARGET, 2016, 7 (25) : 38333 - 38346
  • [5] Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
    C Pawlyn
    M D Bright
    A F Buros
    C K Stein
    Z Walters
    L I Aronson
    F Mirabella
    J R Jones
    M F Kaiser
    B A Walker
    G H Jackson
    P A Clarke
    P L Bergsagel
    P Workman
    M Chesi
    G J Morgan
    F E Davies
    Blood Cancer Journal, 2017, 7 : e549 - e549
  • [6] Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
    Pawlyn, C.
    Bright, M. D.
    Buros, A. F.
    Stein, C. K.
    Walters, Z.
    Aronson, L. I.
    Mirabella, F.
    Jones, J. R.
    Kaiser, M. F.
    Walker, B. A.
    Jackson, G. H.
    Clarke, P. A.
    Bergsagel, P. L.
    Workman, P.
    Chesi, M.
    Morgan, G. J.
    Davies, F. E.
    BLOOD CANCER JOURNAL, 2017, 7 : e549 - e549
  • [7] The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia
    Papakonstantinou, Nikos
    Ntoufa, Stavroula
    Chartomatsidou, Elisavet
    Kotta, Konstantia
    Agathangelidis, Andreas
    Giassafaki, Lefki
    Karamanli, Tzeni
    Bele, Panagiota
    Moysiadis, Theodoros
    Baliakas, Panagiotis
    Sutton, Lesley Ann
    Stavroyianni, Niki
    Anagnostopoulos, Achilles
    Makris, Antonios M.
    Ghia, Paolo
    Rosenquist, Richard
    Stamatopoulos, Kostas
    ONCOTARGET, 2016, 7 (24): : 35946 - 35959
  • [8] Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia
    Chartomatsidou, Elisavet
    Ntoufa, Stavroula
    Kotta, Konstantia
    Rovida, Alessandra
    Akritidou, Maria Anna
    Belloni, Daniela
    Ferrero, Elisabetta
    Trangas, Theoni
    Stavroyianni, Niki
    Anagnostopoulos, Achilles
    Rosenquist, Richard
    Ghia, Paolo
    Papakonstantinou, Nikos
    Stamatopoulos, Kostas
    BLOOD ADVANCES, 2019, 3 (12) : 1891 - 1896
  • [9] Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas
    Wang, Yong
    Chen, Yajing
    Geng, Hua
    Qi, Can
    Liu, Yunde
    Yue, Dan
    TUMOR BIOLOGY, 2015, 36 (09) : 7159 - 7166
  • [10] Overexpression of TCTPmRNA in chronic lymphocytic leukemia indicates inferior prognosis
    Chen, Rui-Ze
    Xia, Yi
    Huang, Ying
    Liang, Jin-Hua
    Wu, Jia-Zhu
    Wang, Li
    Fan, Lei
    Li, Jian-Yong
    Xu, Wei
    LEUKEMIA & LYMPHOMA, 2015, 56 : 136 - 137
12345